ORTHOTROPHIX - Key Persons
David M. Rosen, Ph.D. served as Chief Scientific Officer of OrthoTrophix, Inc. Dr. Rosen is a biochemist, having extensive experience in the drug development process from basic research through late stage development. His experience includes research and development of therapeutic proteins, peptides, and small molecules. Much of his experience has involved research and development of therapeutics and devices in the orthopedic and hard tissue repair fields. Prior to co-founding OrthoTrophix, Inc., Dr. Rosen was the Senior Vice President, Research and Development of Acologix from 2006 to 2010 and Vice President of Research and Development from 2002 to 2006. From March 1999 to July 2002 Dr. Rosen served as Vice President of Operations for Hyseq Pharmaceuticals. He has also held key research and development management and executive positions in public biopharmaceutical companies, including collagen Corporation and Celtrix Pharmaceuticals.
Dawn McGuire, M.D., FAAN serves as Chief Medical Officer of OrthoTrophix, Inc. Dr. McGuire is a board certified neurologist with more than 20 years of executive leadership in drug development. Prior to co-founding OrthoTrophix, Inc., Dr. McGuire was the Chief Medical Officer of Acologix, Inc. from 2007 to 2012 where she led the company's late stage clinical program. At Elan Pharmaceuticals, she was Vice President of Clinical Research, where she served as development leader for Tysabri, a drug now marketed for the treatment of patients with relapsing forms of multiple sclerosis (MS). From 1999 to 2002, Dr. McGuire served as Chief Executive Officer of Eunoe, Inc. Dr. McGuire also holds several academic and service positions, including neurological academy committee memberships, peer review committee membership in the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH), and serves on the Advisory Council of the Gill Heart Institute.
Yoshi Kumagai serves as President and CEO of OrthoTrophix, Inc. Mr. Kumagai has a broad scope of business and product development achievements in the biopharmaceutical industry, where he has held executive positions in several companies and non-profit research institutions. Prior to co-founding OrthoTrophix, Inc., Mr. Kumagai was President and CEO of Acologix, Inc., from 1992 to 2010, where he led discovery through late stage clinical development of multiple therapeutic compounds in the areas of hard tissue and kidney diseases. Mr. Kumagai also worked for Kirin-Amgen, Inc., where he was involved in the development and commercialization of Epogen and Neupogen. In parallel, he served as a General Manager of Research and Development at Gemini Science, Inc., as well as an interim board member of La Jolla Institute for Allergy and Immunology, where he played key roles when the institute became operational.